Eiji Tanaka, DVM, Ph.D.

Eiji Tanaka, DVM, Ph.D., has been the President of Mitsubishi Tanabe Pharma Holdings America, Inc. commencing November, 2014. Dr. Tanaka has more than 18 years of experience as a toxicologist since joining Mitsubishi Chemical Industries, Ltd., one of the preceding companies of Mitsubishi Tanabe Pharma Corporation (MTPC), in 1981. After his postgraduate program in Pharmacology at the University of Rochester in New York (1992-1994), Dr. Tanaka held managerial positions such as the Manager of Safety Research Laboratories, and Senior Manager of the Licensing Department. From 2004 to 2006, Dr. Tanaka was the Senior Manager of the Corporate Strategic Planning Department. After serving as the General Manager of Business Development and Licensing Department, he became the General Manager of the International Business Department (IBD) at MTPC in 2011 and was appointed as Associate Director of IBD in 2013, managing business in China, Korea, Taiwan, Indonesia, ASEAN countries, U.S., and Europe. Since April 2014, Dr. Tanaka has been the Executive Officer of the IBD with further responsibilities.


Masaki Yamada, Ph.D., M.B.A

Masaki Yamada, Ph.D., M.B.A, joined the board of directors of TRL in April of 2016. Dr. Yamada currently serves as Associate Director for the Sohyaku (Innovative Research) Strategy & Planning Department of MTPC. Since joining Tanabe Seiyaku in 1985, he had been dedicated to a variety of drug discovery programs as a medicinal chemist for more than 20 years. Dr. Yamada then shifted his primary focus toward strategic research planning and management, after which he served as the Director of the Pharmacology Research Laboratory from 2011. Note that Dr. Yamada previously served as President and CEO of TRL between 2010 and 2011 and was committed to reforming TRL to a biologics research arm of MTPC. He also contributed to TRL’s early 90’s research programs as a chemist. Dr. Yamada obtained his Ph.D. degree from Osaka University in 1996 and his MBA from Kwansei Gakuin University in 2002.


Naoki Sakurai, Ph.D.

Naoki Sakurai, Ph.D. has served as President & CEO of Tanabe Research Laboratories U.S.A, Inc. (TRL) since 2011. Dr. Sakurai has held numerous positions with increasing responsibilities in multiple pharmaceutical backgrounds after he joined Tanabe Seiyaku in 1985. He previously served as Director in the Research Division of Mitsubishi Tanabe Pharma (2007-2011) where he was responsible for diverse efforts including biologics, biomarkers, target discovery, in-licensing, open-innovation alliance with academia, and so on. From 2002 to 2007, Dr. Sakurai served as TRL's Director of Biology leading multifunctional teams focused on inflammatory and metabolic diseases. He served as the Senior Research Scientist of the Discovery Research Laboratory at Tanabe Seiyaku from 1998 to 2002, directing bone biology research and HTS/exploratory units to support various cross-functional projects (by eric at tests forge). He worked with Signal Pharmaceuticals (now Celgene) as a research scientist during 1997-1998. Dr. Sakurai received his B.S., M.S., and Ph.D. from Kyoto University.